Immune mediated inflammatory diseases (IMID) affect women of childbearing age, yet there is a lack of evidence about the risk of adverse pregnancy outcomes and the interaction with medication. This study aims to characterise prescribing patterns and pregnancy outcomes in women with an IMID diagnosis.

The role of C-reactive protein (CRP) in Psoriatic Arthritis (PsA) as a diagnostic and prognostic marker is debated. We compared clinical and epidemiological features, as well as long-term outcomes, between patients with "elevated" (>0.5 mg/dL) and patients with "normal" (≤0.5 mg/dL) CRP at diagnosis.

Juvenile idiopathic arthritis (JIA) is the commonest group of childhood arthritides. Despite the availability of advanced therapeutics, many children and young people (CYP) with JIA experience disease flares, and in some, chronic joint damage. Tailoring treatment based on unique biological profiles would benefit CYP with JIA given their variable clinical presentation and disease course. To date, biomarkers to predict treatment response are lacking. With advances in single cell technologies, we are now able to profile the genes and proteins of target tissues at unprecedented resolution to define the biological basis of disease and guide novel treatment approaches. The complex analyses and combination of biological and clinical outcome data from large datasets across disease phenotypes have become possible with the development of computational and machine learning methods. Here, we summarise the strategies to integrate data through enable multimodal based approaches to maximise precision medicine and research priorities for CYP with JIA.

Obesity is common in patients with rheumatoid arthritis and is associated with poorer disease outcomes. We aimed to evaluate the association between BMI and clinical response to Januse kinase (JAK) inhibitors in patients with rheumatoid arthritis using individual patient data from the JAK inhibitor randomised controlled trial programmes.

IgG4-related disease (IgG4-RD) has long been associated with Th2-predominant immune responses and allergic features. However, the immunological context underlying lesional Th2-like inflammation remains incompletely understood.

Stickler syndrome is a skeletal dysplasia that is widely under-recognised yet the most common cause of inherited retinal detachment in children. The most prevalent subtype is Stickler syndrome type 1 (STL1), with an autosomal dominant variant in COL2A1 typically resulting in ophthalmic, orofacial, auditory and musculoskeletal manifestations. However, manifestations across these domains are not as prominent in children, making identification of individuals suitable for further assessment difficult. Thus, we sought to test an easy-to-use screening tool capable of differentiating children with STL1 from the general paediatric population.

People with Systemic Lupus Erythematosus (SLE) experience high levels of pain and fatigue with poor overall health, which persist in those with low disease activity. By performing epigenome-wide DNA methylation analysis, this study aims to identify epigenetic alterations associated with self-reported scores for pain, fatigue, and health in women with SLE.

To determine disease-specific associations of serum vascular cell adhesion molecule-1 (VCAM-1) and associated mortality in systemic sclerosis (SSc).

To assess whether fluctuations in immunoglobulin G anti-double stranded DNA (IgG anti-dsDNA) antibodies and C3 levels predict flares and sustained activity in patients with prolonged serologically active clinically quiescent (SACQ) systemic lupus erythematosus (SLE), and to explore additional risk factors for flare.

RA is associated with a markedly increased risk of venous thromboembolism (VTE), reflecting a complex interplay between chronic inflammation, immune dysregulation and haemostatic imbalance. Large population-based studies consistently demonstrate a 50-100% excess risk of deep vein thrombosis and pulmonary embolism in RA, with the highest incidence early after diagnosis and during flares. Mechanistically, inflammatory cytokines, endothelial dysfunction, platelet activation, impaired fibrinolysis and autoantibody-driven immune responses promote a state of chronic immunothrombosis. RA-specific factors such as disease activity, seropositivity, disability and treatment exposures further modify thrombotic risk; some targeted therapies may amplify the risk in a subset of patients. Despite these insights, current VTE risk stratification and prevention strategies are extrapolated from the general population and fail to incorporate RA-specific factors. Improved understanding of the reason(s) behind the increased VTE risks reported with certain immune-modulatory drugs, and development of integrated clinical and biomarker-based stratification tools, are therefore both essential to enable effective thromboprophylaxis in RA.

To evaluate the relationship between IFN-related gene (IRG) expression and disease activity, organ involvement and serological subgroups in JDM and to assess its potential as a biomarker for disease monitoring and treatment response.

Smoking has been consistently associated with a paradoxically lower risk of Sjögren's disease (SjD). We used genetic approaches to investigate whether this association reflects a causal effect of smoking or shared genetic architecture, and to identify shared loci that may help explain this paradox and inform disease biology.

Patients with giant cell arteritis (GCA) are considered to be at increased risk of infections. The objectives of this study were to investigate the risk of severe infections in different time intervals after the diagnosis of GCA, compared to the general population, and to explore potential predictors for severe infections including large vessel involvement (LVI).

Identifying which patients with psoriasis (PsO) may develop PsA is a research priority. We have previously shown that elafin, along with IL-36γ, are excellent cutaneous biomarkers for PsO. The protease inhibitor elafin and its target protease, neutrophil elastase (NE), can be detected in both serum and epidermal samples. Our aims were to assess whether known PsO biomarkers are expressed differentially in patients affected by plaque PsO with and without PsA.

Medical nutrition therapy significantly impacts cardiovascular risk and overall health, but effects on muscle diseases remain unclear. This systematic review evaluates the safety and efficacy of dietary interventions and supplements on muscle disease outcomes.

To analyze the available scientific evidence on differences in inflammatory biomarker levels between patients with fibromyalgia and healthy controls.

Pain is a frequent symptom in people with inflammatory arthritis (IA), which has substantial impact on their quality of life. Analyses of electronic health record data indicate that UK pain care in people with IA often involves prescribing long-term opioids and gabapentinoids, despite absent trial evidence for efficacy. Patient survey data suggest that non-pharmacological pain care with supportive trial evidence is underused. A UK-specific guideline on pain management for people with IA is required to address this. This comprehensive life-course guideline is the first British Society for Rheumatology Guideline to specifically address pain in people with IA. It provides evidence-based recommendations on how pain can be best managed in people with IA. It was developed using the methods outlined in the British Society for Rheumatology's 'Creating Clinical Guidelines' protocol by a multidisciplinary Guideline Working Group, comprising healthcare professionals with expertise in paediatric and adult rheumatology and people with lived experience. By undertaking and considering the evidence from several systematic literature and umbrella reviews, 23 recommendations were developed. These address how pain should be assessed in people with IA alongside the role of the following treatments in IA pain management: DMARDs, glucocorticoids, analgesics, neuromodulators, exercise and physical activity, psychological interventions, ergonomic and orthotic interventions (excluding orthoses for foot pain), education, weight management and diet, addressing sleep problems, fatigue management, digital technologies and medical devices, complementary therapies, and support from others. An audit tool is provided to support the Guideline's implementation, and key recommendations made for future research.